Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GALR2 | O43603 | 6/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | GALR1 | P47211 | 3/20 | 0.43 |
| ▸ | NAPEPLD | Q6IQ20 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238454 | 0.83 | CNR2 (0.50) | LMNAMAPTGALR2GALR1NAPEPLD | |
| SCHEMBL3240907 | 0.82 | GALR2 (0.57) | LMNAMAPTGALR2CCNE1CDK2 | |
| SCHEMBL3246394 | 0.81 | MAPT (0.57) | LMNAMAPTGALR2CCNE1CDK2 | |
| SCHEMBL3244303 | 0.81 | LMNA (0.49) | LMNAMAPTGALR2CCNE1CDK2 | |
| SCHEMBL6790642 | 0.80 | LMNA (0.47) | LMNAMAPTGALR2GALR1ALDH1A1 | |
| SCHEMBL18162511 | 0.80 | LMNA (0.53) | LMNAMAPTGALR2CCNE1CDK2 | |
| SCHEMBL8253195 | 0.80 | MAPT (0.48) | LMNAMAPTGALR2CCNE1CDK2 | |
| SCHEMBL3233185 | 0.79 | LMNA (0.46) | LMNAMAPTGALR2CCNE1CDK2 | |
| SCHEMBL8254119 | 0.79 | KDM4E (0.48) | LMNAMAPTGALR2GALR1ALDH1A1 | |
| SCHEMBL8256643 | 0.79 | MAPT (0.48) | LMNAMAPTGALR2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2007-11-08 | — | — | US | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | LMNA 1768/4885MAPT 3040/4885GALR2 2/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | LMNA 1768/4885MAPT 3040/4885GALR2 2/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | LMNA 2398/4885MAPT 1723/4885GALR2 2/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | LMNA 2883/4885MAPT 3177/4885GALR2 2/4885 |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | LMNA 1798/4885MAPT 2990/4885GALR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.